[A non-selective beta-adrenergic antagonist with antihypertensive and antiarrhythmic activities. Nadolol competitively blocks beta-1 adrenergic receptors located in the heart and vascular smooth muscle, therefore inhibiting the effects of catecholamines, epinephrine, and norepinephrine. As a result, this agent produces negative inotropic and chronotropic effects. Nadolol exerts its antiarrhythmic effect via impairment of atrioventricular (AV) node conduction and reduction of sinus rate. In addition, nadolol blocks beta-2 adrenergic receptors located in the bronchiole smooth muscle resulting in vasoconstriction. Furthermore, beta-2 receptor blockage within the juxtaglomerular apparatus leads to the inhibition of renin production, as well as subsequent reduction in angiotensin II and aldosterone levels, thereby inhibiting angiotensin II and aldosterone dependent vasoconstriction and water retention. ( NCI )]
UMLS (NCI) C0027302 - Organic Chemical
- Pharmacologic Substance
Relation/PAR: Propanolamines
[CV100] BETA-BLOCKERS/RELATED
Relation/CHD: NADOLOL 120 MG
NADOLOL 20 MG
NADOLOL 40 MG
NADOLOL 80 MG
NADOLOL 160 MG